Cardiff Oncology, Inc.
CRDF
$1.82
$0.010.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 35.90% | 19.26% | -3.79% | -13.97% | 0.57% |
| Total Depreciation and Amortization | -0.45% | -2.18% | 0.44% | -1.30% | -2.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.56% | -18.09% | 12.54% | 17.40% | -4.56% |
| Change in Net Operating Assets | 91.74% | -123.28% | 590.69% | -435.80% | 262.69% |
| Cash from Operations | 44.92% | -30.09% | 34.91% | -24.61% | 1.81% |
| Capital Expenditure | 100.00% | 30.77% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.61% | 305.33% | 66.01% | -423.30% | 147.82% |
| Cash from Investing | 5.80% | 303.89% | 65.83% | -423.30% | 147.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10,112.00% | -- | -100.00% | -99.99% | 494.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 10,112.00% | -- | -100.00% | -99.99% | 494.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,230.20% | 95.12% | 51.38% | -171.23% | 408.37% |